Twelve Innovative Biopharma Companies Secure New Funding Rounds
LongBio
Next-Generation Large Molecule Antibody Developer
BioAge
Drug Discovery Platform Developer
Vicebio
Developer of New Vaccines
In terms of drug types,Gene Therapy, Cell Therapy, Bispecific Antibodies, Nucleic Acid DrugsNew molecules remain a popular investment area. In terms of regional distribution,Biotechs that received financing this week are mainly from the United States, accounting for 50%.，Next are China and Italy.。 In terms of amount,New Star in Weight Loss Therapy Development: BioAge Labs The Highest Financing Amount, the company raised nearly 200 million US dollars through an IPO on Nasdaq.
LongBio: Completes Nearly 100 Million Yuan in B2 Round Financing
LongBio announced the completion byQiming Venture Partners Leads the InvestmentTheNearly 100 Million USD in Series B2 FinancingThe proceeds from the financing will be used to advance its core projects in clinical research in China, accelerate the product’s market launch process, and support the layout of the international market.
LongBio Focuses on DevelopmentAllergyAndInnovative Antibody Drugs in the Complement Field。Among them,Next-Generation Anti-IgE Antibody LP-003Has demonstrated good efficacy and safety in Phase II clinical trials for the treatment of allergic rhinitis, and Phase III clinical trials are currently underway. Market authorization is expected to be filed in the second half of 2025.
Another Core Project of the CompanyLP-005 is a bispecific antibody targeting complement, has initiated a Phase II clinical trial for the treatment of the rare disease paroxysmal nocturnal hemoglobinuria (PNH).LongBio will complete the U.S. IND filings for these two products in the near future and initiate overseas bridging clinical studies.
VTX3232 isAn orally administered, selective, CNS-penetrant NLRP3 inhibitor, showing potential therapeutic effects for a series of neuroinflammatory and neurodegenerative diseases. Currently, the product is undergoing Phase IIa trials for early Parkinson's disease and Phase II trials for obesity and other cardiometabolic risk factors. Data from these two trials are expected to be released in 2025.
LIfT Raises £10 Million
LIfT BioSciences Announces £10 Million Raised in First Close of Series A Financing, with Second Close Expected in Q1 2025. This Round is Supported by New Investor Sijbrandij Foundation and Existing Investors Lifespan Vision Ventures, Starbloom Capital, and Jonathan Milner.
LIfT Corporation is developingA Breakthrough Allogeneic Innate Cell Therapy Platform, the platform can generateA Novel Type of Bone Marrow Cell —— Immunomodulatory α Neutrophils (IMANs)IMANs can recruit the patient's own immune cells by modulating the tumor microenvironment, directly and indirectly killing cancer cells. This round of financing will be used to advance the company’s IMANs into the clinical trial stage.
Eradivir Completes $10.25 Million Series A Financing
Eradivir Announces Completion of $10.25 Million Series A Financing; Proceeds to Support Phase Ⅱa Challenge Study for EV25 Influenza Treatment. Eradivir is aDevelopment of Antiviral Therapeutic DrugsPreclinical biotechnology company.
EV25 is a new influenza drug that inhibits viral replication and kills influenza viruses and infected cells by delivering an immune load containing haptens, which specifically attach to the surface of viruses and virus-infected cells. In preclinical models, EV25 has demonstrated potential superior to current standard influenza care, reducing the number of live viruses to undetectable levels within 24 hours after administration.
Aptadir, a New Star in RNA Therapy, Officially Established
Aptadir Therapeutics Announces Official LaunchCommitted to Developing Innovative RNA-Based Therapies, treating refractory cancers and genetic diseases. The company's first R&D project is under development for the treatment of myelodysplastic syndromes (MDS), with the goal of entering clinical trials by the end of 2025.
Aptadir's technical platform is based on RNA molecules capable of interacting with DNA methyltransferases (DNMTs). These RNA molecules can precisely block abnormal DNA methylation of specific genes, reactivating genes that were previously silenced due to hypermethylation, thereby addressing the root causes of certain diseases. The platform enables the generation of various RNA molecules targeting suppressed genes in cancers and genetic disorders to restore their function.
